Irbesartan for the Prevention of Atrial Arrhythmias and Cardiac Electrical Remodeling
| < back
The trial evaluates whether in hypertensive patients with sinus node dysfunction and permanent atrial or dual- chamber pacemakers, who have atrial high-rate episodes (AHRE), treatment with the angiotensin receptor blocker irbesartan, will prevent the development of electrical and structural remodeling, and thus reduce the rate of recurrent AHRE and ultimately atrial fibrillation (AF).
Study Design: Randomized, Double Blind, Placebo Controlled.
Intervention: Irbesartan vs. placebo.
Length of Study: 6 years
# of Patients: 200
Patient Populations: Pacemaker patients with Hypertension and AHRE.
Available upon study completion.
Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)
Not available at this time.